Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07154823 · ClinicalTrials.gov registry record
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
A clinical trial of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML), sponsored by Tempus AI.
- Recruiting
- Registry status
- 550
- Enrollment target
- 5
- Study locations
NCT07154823: Recruiting study of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML), sponsored by Tempus AI.
NCT07154823 is a study of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML) that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 550 participants, above the 477-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (15% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07154823, a study of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML), is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 5
- Study locations
Study Summary
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Primary Outcome
The goal of this biomarker discovery registry is to assess DNA and RNA expression patterns and potential biomarkers in biospecimens collected at baseline and throughout treatment, with the goal of generating hypotheses about predictive markers for therapy selection, prognostic indicators, and potential mechanisms of resistance to standard-of-care therapies across multiple hematologic indications.
Conditions Studied
Interventions
- OTHER None - Observational Study
Study Locations (5)
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Nevada
- Cancer Care Specialists of Reno - Reno
Ohio
- Taylor Cancer Research Center - Maumee
Pennsylvania
- Cancer Care Associates of York - York
South Dakota
- Avera Cancer Institue - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2035-11 |
What NCT07154823 shows while recruiting
NCT07154823 is an observational study that tracks outcomes without assigning an intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 477-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (15% higher).
The record links to 2 conditions, with Follicular Lymphoma (FL) appearing as the primary indexed condition, and to 1 intervention - of which None - Observational Study is the first listed.
NCT07154823 lists 5 locations in 5 states (Maryland, Nevada, Ohio).
Frequently Asked Questions
What is clinical trial NCT07154823 about?
NCT07154823 is a clinical study titled "A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies". The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates...
What is the current status of trial NCT07154823?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2026-01-27. Estimated completion is 2035-11.
What conditions does trial NCT07154823 study?
This clinical trial studies the following conditions: Follicular Lymphoma (FL), Acute Myeloid Leukaemia (AML).
What interventions are being tested in trial NCT07154823?
The interventions under investigation include: None - Observational Study (OTHER).
Who is sponsoring clinical trial NCT07154823?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07154823 being conducted?
This trial has 5 study locations across Maryland, Nevada, Ohio, Pennsylvania, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma (FL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07154823's enrollment target sits among peer trials
550 5th of 10 higher than 6 of 10 other Follicular Lymphoma (FL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma (FL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RECRUITING · Phase 2
-
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI